摘要:

Thrombelastgram (TEG) is an old but automated instrument that demonstrates changes occurring during blood coagulation and fibrinolysis. TEG was evaluated to be better than activated partial thromboplastin time (APTT) as a monitor of hemostatic effects when using recombinant factor VIla (65-80 μg/kg) in 3 hemophilia A patients with a high titer of factor VIII inhibitors. TEG was more suitable than APTT, because r, r+k and ma values of TEG were normalized at least for 4 h after the infusion, whereas APTT was variably shortened and was not always maintained at a normal level for 4 h

ISSN:1424-8832    

DOI:10.1159/000217256

出版商:S. Karger AG    

年代:1996

数据来源: Karger

摘要:

A novel investigational product, recombinant factor VIla, manufactured by Novo Nordisk, is presently in clinical trial for evaluation of safety and efficacy when used in the home setting in patients with hemophilia A and B with inhibitors for control of hemostasis in mild to moderate joint, muscle and mucocutaneous bleeding episodes. The clinical trail is an open label, multicenter, uncontrolled study in which 60 patients are enrolled and treated for 1 year with the goal of accumulating 120 evaluable bleeding episodes. Reported here is an outline of the study, review of currently enrolled patient demographics, and the data accumulated to date from the Indiana Hemophilia Comprehensive Center.

ISSN:1424-8832    

DOI:10.1159/000217257

出版商:S. Karger AG    

年代:1996

数据来源: Karger

摘要:

Two siblings affected by type III von Willebrand’s disease with precipitating alloantibodies against von Willebrand’s factor (vWF) and not susceptible to treatment with factor VIII/ vWF concentrates received recombinant activated factor VII for oral surgery. This therapy, combined with antifibrinolytic drugs and local application of fibrin glue, seems to be effective and safe. It may be considered a promising approach to the management of this rare condit

ISSN:1424-8832    

DOI:10.1159/000217258

出版商:S. Karger AG    

年代:1996

数据来源: Karger

摘要:

Factor VII deficiency is a relatively infrequent hereditary bleeding disorder. Recombinant factor VIla has been used to treat patients with factor VII deficiency with bleeding episodes or undergoing surgery. The drug has shown a high efficacy rate and will provide factor VH-deficient patients with a therapeutic agent that is not derived from human plasma.

ISSN:1424-8832    

DOI:10.1159/000217259

出版商:S. Karger AG    

年代:1996

数据来源: Karger

摘要:

Platelets play a central role in primary hemostasis. The role of the coagulation mechanism during early stages of hemostasis is less clear, although increasing evidence is emerging indicating the ultimate importance of the factor VII (FVII)-tissue factor-dependent coagulation system in providing the first thrombin molecules necessary for the platelet activation to occur. Supporting this, early fibrin formation has been reported to occur within the bleeding time wound and infusion of recombinant FVIIa (rFIIa) has been shown to shorten the bleeding time in rabbits. We have investigated whether infusion of rFVIIa would enhance fibrin formation in bleeding time wounds in patients with thrombocytopenia as reflected by a shortening of the bleeding time. A reduction of the bleeding time was found in 55/105 cases (52%). The decrease was significantly more pronounced when the platelet count exceeded 20 × 109/l. With the exception of an anaphylactoid reaction in 1 patient, no major adverse reactions related to the study drug were observed. Nine infusions of rFVIIa were given to 8 thrombocytopenic patients with overt bleeding. One patient received two infusions. Bleeding decreased in all patients and stopped in 6 patients

ISSN:1424-8832    

DOI:10.1159/000217260

出版商:S. Karger AG    

年代:1996

数据来源: Karger

ISSN:1424-8832    

DOI:10.1159/000217261

出版商:S. Karger AG    

年代:1996

数据来源: Karger

ISSN:1424-8832    

DOI:10.1159/000217262

出版商:S. Karger AG    

年代:1996

数据来源: Karger

ISSN:1424-8832    

DOI:10.1159/000217231

出版商:S. Karger AG    

年代:1996

数据来源: Karger